Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10927575 | 0.98 | LMNA (0.48) | LMNAGSK3BF7F3MAP2K4 | |
| SCHEMBL10931244 | 0.98 | LMNA (0.48) | LMNAGSK3BF7F3MAP2K4 | |
| SCHEMBL6612568 | 0.88 | GSK3B (0.56) | LMNAGSK3BMAP2K4KEAP1NFE2L2 | |
| SCHEMBL13062144 | 0.86 | SIRT1 (0.52) | GSK3BMAP2K4FADS1SIRT1JAK2 | |
| SCHEMBL8323107 | 0.85 | FADS1 (0.40) | GSK3BF7F3MAP2K4FADS1 | |
| SCHEMBL9323964 | 0.82 | SMN1; SMN2 (0.53) | GSK3BMAP2K4FADS1SIRT1JAK2 | |
| SCHEMBL13013280 | 0.82 | GSK3B (0.46) | GSK3BMAP2K4FADS1SIRT1JAK2 | |
| SCHEMBL30965223 | 0.81 | TSHR (0.54) | LMNAMAP2K4FADS1KDM4EMEN1 | |
| SCHEMBL7581326 | 0.81 | LMNA (0.49) | LMNAGSK3BJAK2JAK1KDM4E | |
| SCHEMBL14979246 | 0.81 | TSHR (0.54) | LMNAMAP2K4FADS1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| CN-103391936-A | Anticancer agent | NAT UNIV CORP UNIV TOKYO | 2013-11-13 | — | — | CN | disclosed |
| US-7855203-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855203-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2010079805-A1 | METHOD TO RESTORE MALE STERILITY IN GRAMINEOUS PLANTS AND MALE STERILITY RESTORATIVE AGENT | 国立大学法人東北大学 (JP) | 2010-07-15 | — | — | WO | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-5703070-A | PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-12-30 | — | — | US | disclosed |
| US-5330997-A | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1994-07-19 | — | — | US | disclosed |
| US-5236945-A | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0325375-B1 | 1H-INDAZOLE-3-ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1989006651-A1 | 1H-INDAZOLE-3-ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0325375-A1 | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0008759-B1 | NEW PROCESS FOR PREPARING AN 1H-INDAZOL-3-YLACETIC ACID DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-12-01 | — | — | EP | disclosed |
| EP-0008759-A2 | New process for preparing an 1H-indazol-3-ylacetic acid derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-03-19 | — | — | EP | disclosed |
| US-4008070-A | ALKYL 5-HALO-1H-INDAZOLE-3-ACETATE | NISSAN CHEMICAL INDUSTRIES CO., LTD. (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | LMNA 3426/4885GSK3B 601/4885F7 4847/4885 |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | LMNA 2025/4885GSK3B 2572/4885F7 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.